

# IMMUNOTOXICITY TESTING: ICH GUIDELINE S8 AND RELATED ASPECTS

HANS-GERD PAUELS<sup>1</sup> AND JOHN TAYLOR<sup>2</sup>

<sup>1</sup>*Dr. Pauels—Scientific and Regulatory Consulting, Münster, Germany*

<sup>2</sup>*ProPhase Development Ltd, Harrogate, United Kingdom*

## Contents

- 1 Introduction
- 2 Categories of Immunotoxicity
  - 2.1 Immunosuppression
  - 2.2 Unintended Immunostimulation
  - 2.3 Immunogenicity
  - 2.4 Allergenicity
  - 2.5 Autoimmunity
- 3 Regulatory Considerations
  - 3.1 History of Regulatory Guidelines
  - 3.2 Current Developments for Pharmaceuticals
  - 3.3 The Common Spirit of Regulatory Immunotoxicity Guidelines
- 4 Immunotoxicity Testing Strategies
  - 4.1 Initial Considerations
  - 4.2 Timing of Immunotoxicity Studies
  - 4.3 Choice of Test Species
  - 4.4 Immunotoxicity Alerts
  - 4.5 Decision Tree
- 5 Immunotoxicity Testing Protocols: Immunosuppression
  - 5.1 Basic Testing
  - 5.2 Additional Testing
- References